Core Framework & Diagram Multiple Sclerosis
July 28, 20261 Min Read Psoriasis
July 28, 2026When the immune system begins attacking the 'insulation' around your brain's wiring
——An autoimmune war waged inside the nervous system — same diagnosis, ten completely different stories.
I. A confusing disease: the same diagnosis, ten completely different stories
MS has one characteristic that makes it especially hard to explain to outsiders: every patient's experience may be completely different. One person's first attack is sudden blurry vision for a few days, then complete recovery with no major problems for ten years. Another quickly progresses to walking difficulty from the very first attack. Another's main symptom is extreme fatigue that no one around them can see at all. This high individual variability comes from a basic fact: MS lesions can appear anywhere in the central nervous system (brain and spinal cord). Damage to the optic nerve affects vision; in motor cortex or spinal cord, affects limb strength; in the cerebellum, affects balance and coordination; in the frontal lobe, affects cognition and emotion.
This also means 'I have MS' cannot tell anyone how difficult your life actually is. This invisible, highly individualized disease course is the fundamental reason MS patients often feel misunderstood. This invisibility isn't only a psychological challenge — it's also a real difficulty in social support and workplace adaptation: employers, family members, and friends often struggle to understand why someone who appears 'normal' sometimes can't work or function normally.
2. The blood-brain barrier: a defensive line breached
The brain has a special protection mechanism called the Blood-Brain Barrier (BBB). Composed of specialized endothelial cells, it blocks most substances in blood from entering the brain — including immune cells. Normally, immune cells shouldn't freely pass in and out of the brain. MS's pathological process begins with blood-brain barrier disruption.
Under the combined effects of genetic susceptibility, viral infection, vitamin D deficiency, and other factors, self-reactive T cells are activated and begin attacking myelin proteins. These T cells can secrete specific cytokines that disrupt blood-brain barrier integrity, opening a passage for themselves and other inflammatory cells to enter the brain. Once inside the CNS, these T cells and subsequently entering macrophages and B cells begin launching inflammatory attacks around the myelin.
This process is staged: inflammation erupts, symptoms appear; inflammation subsides, some myelin repairs (oligodendrocytes can re-wrap damaged nerve fibers), symptoms partially or completely remit. This is the classic disease course pattern of relapsing-remitting MS. But each relapse adds a bit more to axon damage accumulation. When oligodendrocytes' repair capacity is exhausted, patients transition from relapsing-remitting to secondary-progressive MS, with continuous functional decline beginning.
3. Why are women more likely to get multiple sclerosis?
MS's sex disparity is an immunological phenomenon worth deep reflection. Female prevalence is approximately three times male, and this ratio has been increasing in recent decades — approximately 2:1 in the 1950s, now approaching 3:1. This time trend suggests environmental or lifestyle factors are playing increasingly important roles (genetic factors don't change rapidly within a few decades).
The mechanism of sex disparity involves multiple levels. Estrogen has universal pro-inflammatory effects on the immune system; women overall have stronger adaptive immune responses, which is evolutionarily advantageous (stronger anti-infection capacity) but simultaneously increases autoimmune risk. The X chromosome carries many immune-related genes; women have two X chromosomes, and even if one is inactivated, this may affect immune regulation. Additionally, modern lifestyle changes — including vitamin D deficiency (reduced sun exposure), altered gut microbiome, rising obesity rates — may affect women differently than men in ways related to rising MS risk.
4. The most interesting geographic pattern: the further from the equator, the higher the incidence
MS has an unusual geographic distribution: the higher the latitude, the higher the incidence. Northern Europe, Canada, northern United States, southern Australia have the world's highest MS incidence. Tropical regions have extremely low incidence. This pattern has been further verified in migration studies: moving from low-latitude to high-latitude regions before puberty brings disease risk close to the destination's level; moving as an adult keeps risk at the origin's level.
This 'latitude effect' is most explained by vitamin D. High-latitude regions have less sunlight; skin synthesizes vitamin D less efficiently; vitamin D deficiency is widespread in these regions. And vitamin D is an important immune regulatory molecule — it can promote Treg cell development and suppress excessive autoimmune responses. Multiple studies show MS patients' vitamin D levels are generally low, and vitamin D supplementation (reaching adequate serum levels) has some association with reduced MS relapse rates. This isn't a treatment, but a risk factor worth taking seriously.
5. Treatment revolution: from steroids to precision immune modulation
MS treatment has experienced a revolution over the past thirty years. Before the 1990s, MS had almost no effective disease-modifying therapy (DMT). In 1993, the first DMT (interferon-β) was approved, opening a new era. In the thirty years since, over twenty DMTs have come to market: from injectable immune modulators, to oral lymphocyte-blocking drugs, to highly effective monoclonal antibodies (like Natalizumab, specifically blocking immune cells from crossing the blood-brain barrier).
The latest advances include anti-CD20 B cell-targeting antibodies (Ocrelizumab, Ofatumumab), which in clinical trials showed efficacy even against primary-progressive MS — a major breakthrough after years of having almost no effective DMT for this form. Treatment strategy increasingly favors 'early high-efficacy treatment' — using high-efficacy DMT at initial diagnosis rather than starting with mild drugs and escalating only when they fail. Evidence shows early high-efficacy treatment better protects axons and prevents long-term disability accumulation. Time is neurons — the earlier effective treatment begins, the more neurological function is preserved.
6. Lifestyle effects on multiple sclerosis
Smoking is one of MS's most established lifestyle risk factors: smokers have higher MS risk, and patients who continue smoking after diagnosis progress to secondary-progressive MS faster with more disability accumulation. Quitting smoking is one of the most important lifestyle interventions an MS patient can make.
Regular moderate-intensity exercise was previously warned against due to concerns that 'fatigue would worsen symptoms.' This advice has now been reversed — extensive evidence shows regular aerobic exercise can improve MS patients' fatigue, mood, cognitive function, and quality of life, without worsening relapses.
Maintaining adequate vitamin D (serum 25-OH-D above 50–80 nmol/L) is associated with lower relapse rates, and supplementation is low-risk for MS patients. Obesity, especially adolescent obesity, is associated with elevated MS risk and may aggravate the inflammatory burden after diagnosis. Maintaining healthy body weight is a meaningful auxiliary management strategy.
7. MS daily life challenges and coping
Fatigue is one of MS's most common, most quality-of-life-affecting, and hardest-to-explain-to-others symptoms. It's not fatigue that improves with rest — it's deep neurological fatigue, with little connection to how much sleep was had. Understanding this fatigue's neurobiological basis (decreased nerve conduction efficiency from demyelination, and the metabolic consumption of continuous CNS inflammation) is the first step for patients and their surroundings to build understanding.
Cognitive changes appear in approximately fifty percent of MS patients, including memory decline, slower processing speed, difficulty concentrating — collectively called 'MS brain fog.' These changes usually don't reach dementia severity but are sufficient to affect work efficiency and daily management. Regular cognitive training, organized scheduling tools, and reasonable work environment adjustments are all practically helpful coping strategies.
Frequently Asked Questions